Nowa metoda zapobiegania półpaścowi i neuralgii popółpaścowej -- szczepienie szczepem Oka. Wskazania, skuteczność i bezpieczeństwo szczepienia

Białynicki-Birula, Rafał; Gajdzis, Paweł
June 2007
Clinical Dermatology / Dermatologia Kliniczna;2007, Vol. 9 Issue 2, p118
Academic Journal
Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus (VZV) that has been latent in sensory ganglia since primary VZV infection. HZ is mainly a disease of individuals over the age of 60 years and/or immunocompromised patients. Reactivation is a result of a decline in VZV-specific cell-mediated immunity (CMI), specifically a decreased T-cell proliferation in response to VZV antigen. The most feared and debilitating complication of HZ is postherpetic neuralgia (PHN). Current treatment of acute VZV reactivation and pain typically involves antiviral therapy, but no antiviral treatment has been shown to enough effectivelly prevent PHN. The most promising intervention is the use of a VZV/Oka vaccine to stimulate waning CMI and prevent reactivation. Low VZV/Oka titre vaccine trials failed to respond to vaccination or did not retain a response for more than a year. The effectiveness of a high VZV/Oka titre vaccine has been examined in a large randomised, double-blind, placebo-controlled multi-centre trial (Shingles Prevention Study). The use of the zoster vaccine reduced the incidence of HZ by 51.3%, reduced the incedence of PHN by 66.5% and reduced the burden of illness due to HZ by 61.1% during more than 3 years of surveillance. Zoster vaccine was generally well tolerated and safety.


Related Articles

  • Herpes Zoster Infection. Jacobsen, Emily; Hull, Claire E. // Clinician Reviews;Aug2013, Vol. 23 Issue 8, p42 

    The article discusses the management and treatment of herpes zoster (HZ) infection. HZ is commonly called shingles and exhibits a reactivation of the chickenpox virus. The author presents the etiology of HZ, the various treatment options for HZ infection such as antiviral agents and topical...

  • Chickenpox -- Capture It or Expect an Outbreak. Stanley T. Bohinski, // Sheriff;Jan/Feb2007, Vol. 59 Issue 1, p31 

    The article offers information about chickenpox and its ramifications. Two illnesses familiar with most people yet commonly misunderstood are chickenpox and shingles. Chickenpox and shingles are manifestations of the same virus called Varicella-zoster virus. Working in a correctional and...

  • Boy, 11, With Puzzling Rash. Drennen, Lisa; Kaufmann, Judith A. // Clinician Reviews;Jun2007, Vol. 17 Issue 6, p52 

    The article presents the case of an 11-year-old boy who was diagnosed with herpes zoster (HZ). HZ, or shingles, is a reactivation of, or secondary infection, by the varicella-zoster virus (VZV), can also be seen on rare occasions as a breakthrough varicella rash after administration of he...

  • A Shingles Vaccine. Gorman, Christine // Time;6/13/2005, Vol. 165 Issue 24, p67 

    Reports on an experimental vaccine that cuts the risk of shingles, and its painful side effects, by more than half. How anyone who has ever had chicken pox is at risk of developing shingles; Information on the new vaccine, which was tested in an unusually large study; Outlook for approval;...

  • Zoster Vaccine Live (Oka/Merck): A Viewpoint by Robert Johnson. Johnson, Robert // Drugs & Aging;2006, Vol. 23 Issue 6, p532 

    The article comments on the effectiveness of ZOSTAVAX® the Oka/Merck strain varicella zoster virus vaccine, in reducing the incidence of herpes zoster. The author stressed that herpes zoster is not a benign disease. The medical treatment for herpes zoster including hospitalization is poorly...

  • THE 15-MINUTE VISIT: Don't foster zoster. Watson, Linwood W. // Patient Care for the Nurse Practitioner;Jul2007, Vol. 10 Issue 7, p15 

    The article describes the case of a 75-year-old man with systolic hypertension, who developed shingles or herpes zoster. Shingles can develop later in life from varicella zoster virus (VZV) vaccination. It can lead to significant neurologic complications and debility. The patient was told that...

  • Zoster Vaccine Live (Oka/Merck): A Viewpoint by Anthony L. Cunningham. Cunningham, Anthony L. // Drugs & Aging;2006, Vol. 23 Issue 6, p532 

    The article comments on the effectiveness of ZOSTAVAX® the Oka/Merck strain varicella zoster virus vaccine, in reducing the incidence of herpes zoster. The author stressed that herpes zoster therapy significantly helped in reducing the incidence and the duration of severe pain. The...

  • Similar herpes zoster incidence across Europe:results from a systematic literature review. Pinchinat, Sybil; Cebrián-Cuenca, Ana M.; Bricout, Hélène; Johnson, Robert W. // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Herpes zoster (HZ) is caused by reactivation of the varicella-zoster virus (VZV) and mainly affects individuals aged ⩾50 years. The forthcoming European launch of a vaccine against HZ (Zostavax®) prompts the need for a better understanding of the epidemiology of HZ in Europe....

  • Comparison of Varicella-Zoster Virus-Specific Immunity of Patients with Diabetes Mellitus and Healthy Individuals. Okamoto, Shigefumi; Hata, Atsuko; Sadaoka, Kay; Yamanishi, Koichi; Mori, Yasuko // Journal of Infectious Diseases;11/15/2009, Vol. 200 Issue 10, p1606 

    Cell-mediated immunity (CMI) has been shown to be critical for the prevention and control of varicella-zoster virus (VZV)-related diseases. Because a large population-based study has revealed that diabetes mellitus is a risk factor for herpes zoster, we studied VZV-specific immune responses of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics